Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: A systematic review and meta-analysis Review
| Authors: | Patel, P.; Robinson, P. D.; Wahib, N.; Cheung, P.; Wong, T.; Cabral, S.; Parker, A.; Cohen, M.; Devine, K.; Gibson, P.; Holdsworth, M. T.; Neumann, E.; Orsey, A.; Phillips, R.; Spinelli, D.; Thackray, J.; van de Wetering, M.; Woods, D.; Sung, L.; Dupuis, L. L. |
| Review Title: | Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: A systematic review and meta-analysis |
| Abstract: | Purpose: To identify effective and safe interventions to prevent acute phase chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric patients. Methods: We conducted a systematic review of randomized trials evaluating interventions to prevent acute CINV. Outcomes assessed were complete chemotherapy-induced vomiting (CIV) control, complete chemotherapy-induced nausea (CIN) control, complete CINV control, and discontinuation of antiemetics due to adverse effects. Results: The search identified 65,172 citations; 744 were evaluated at full-text, and 295 (25 pediatric) met eligibility criteria. In patients receiving highly emetogenic chemotherapy (HEC), complete CIV (risk ratio (RR) 1.23, 95% confidence interval (CI) 1.05–1.44) and CIN (RR 1.34, 95% CI 1.10–1.62) control improved when olanzapine was added. The addition of a neurokinin-1 receptor antagonist (NK1RA) to a corticosteroid plus a serotonin-3 receptor antagonist (5HT3RA) also improved complete CIV (RR 1.11, 95% CI 1.08–1.14) and CIN (RR 1.05, 95% CI 1.01–1.08) control. Compared to granisetron/ondansetron, palonosetron provided improved complete CIV control when the 5HT3RA was given alone or when combined with dexamethasone. In patients receiving moderately emetogenic chemotherapy (MEC), dexamethasone plus a 5HT3RA improved complete CIV control compared to a 5HT3RA alone (RR 1.29, 95% CI 1.21–1.39). Only a single meta-analysis evaluating the safety outcome was possible. Conclusions: For patients receiving HEC, various antiemetic regimens improved CIV and CIN control. For patients receiving MEC, administration of a 5HT3RA plus dexamethasone improved CIV control. Analysis of antiemetic safety was constrained by lack of data. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| Keywords: | adult; cancer chemotherapy; child; controlled study; treatment response; review; drug efficacy; drug safety; drug withdrawal; monotherapy; antineoplastic agents; chemotherapy; outcome assessment; antineoplastic agent; neoplasm; neoplasms; nausea; vomiting; haloperidol; olanzapine; dexamethasone; publication; chemotherapy induced emesis; prednisolone; add on therapy; systematic review; granisetron; ondansetron; methylprednisolone; mirtazapine; antiemetic agent; antiemetics; hydrocortisone; corticosteroid; disease control; metoclopramide; adverse drug reaction; meta analysis; pediatrics; serotonin 3 antagonist; aprepitant; supportive care; randomized controlled trial (topic); comparative effectiveness; fosaprepitant; palonosetron; corticosteroid therapy; neurokinin 1 receptor antagonist; combination drug therapy; chemotherapy induced nausea and vomiting; humans; human; male; female; netupitant plus palonosetron; pediatric patient; chemotherapy induced nausea; fosnetupitant |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 30 |
| Issue: | 11 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2022-11-01 |
| Start Page: | 8855 |
| End Page: | 8869 |
| Language: | English |
| DOI: | 10.1007/s00520-022-07287-w |
| PUBMED: | 35953731 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 December 2022 -- Source: Scopus |
